Readout LOUD Podcast: What Vinay Prasad’s appointment means for FDA

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public persona suited for government service?

We discuss these and other burning questions on a new episode of “The Readout LOUD,” STAT’s biotech podcast.

Matt Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad’s tenure could be.

For more on what Prasad said in his first speech to the Food and Drug Administration staff, go here; for more on Prasad’s philosophies on clinical trials and other hot topics, go here; to read STAT’s 2017 profile of Prasad, go here; and sign up for Adam’s Biotech Scorecard newsletter here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.